Status:
COMPLETED
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
Lead Sponsor:
Pontificia Universidad Catolica de Chile
Conditions:
Covid19
COVID-19 Vaccines
Eligibility:
All Genders
18+ years
Brief Summary
Despite COVID-19 pandemic having started more than one year ago, there are still limited treatment options for these patients, and over 145 million cases and 3 millions deaths have ensued worldwide. F...
Eligibility Criteria
Inclusion
- General
- Eastern Cooperative Oncology Group \< 3
- Vaccination with 2 doses of Coronavac vaccine
- General
Exclusion
- Previous SARS-CoV-2 infection
- Vaccination with Coronavac more than 12 weeks before informed consent
- Intravenous immunoglobulin therapy 60 days before informed consent
- Any condition, that could interfere with the participant's participation during the study in the opinion of the treating investigator.
- Cancer Cohort
- Inclusion Criteria:
- Diagnosis of cancer in the previous 5 years (consistent biopsy is required).
- Life expectancy more than 12 weeks
Key Trial Info
Start Date :
May 12 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT04888793
Start Date
May 12 2021
End Date
November 1 2021
Last Update
November 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Red de Salud UC Christus
Santiago, Chile